메뉴 건너뛰기




Volumn 48, Issue 3, 2016, Pages 843-851

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

EID: 84986182380     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01966-2015     Document Type: Article
Times cited : (140)

References (27)
  • 1
    • 79951844263 scopus 로고    scopus 로고
    • Clinical course and prediction of survival in idiopathic pulmonary fibrosis
    • Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 431-440
    • Ley, B.1    Collard, H.R.2    King, T.E.3
  • 2
    • 79952717349 scopus 로고    scopus 로고
    • An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
    • Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 788-824
    • Raghu, G.1    Collard, H.R.2    Egan, J.J.3
  • 3
    • 84861911665 scopus 로고    scopus 로고
    • An earlier and more confident diagnosis of idiopathic pulmonary fibrosis
    • du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-146.
    • (2012) Eur Respir Rev , vol.21 , pp. 141-146
    • Du Bois, R.M.1
  • 4
    • 33744916992 scopus 로고    scopus 로고
    • Classification and natural history of the idiopathic interstitial pneumonias
    • Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285-292.
    • (2006) Proc Am Thorac Soc , vol.3 , pp. 285-292
    • Kim, D.S.1    Collard, H.R.2    King, T.E.3
  • 5
    • 84930673517 scopus 로고    scopus 로고
    • Natural history of idiopathic pulmonary fibrosis
    • Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med 2015; 109: 661-670.
    • (2015) Respir Med , vol.109 , pp. 661-670
    • Kim, H.J.1    Perlman, D.2    Tomic, R.3
  • 6
    • 84455168726 scopus 로고    scopus 로고
    • Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference
    • du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
    • (2011) Am J Respir Crit Care Med , vol.184 , pp. 1382-1389
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 7
    • 84862826491 scopus 로고    scopus 로고
    • Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
    • Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
    • (2012) Thorax , vol.67 , pp. 407-411
    • Richeldi, L.1    Ryerson, C.J.2    Lee, J.S.3
  • 8
    • 84875208959 scopus 로고    scopus 로고
    • Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: Making a silk purse from a sow's ear
    • Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax 2013; 68: 309-310.
    • (2013) Thorax , vol.68 , pp. 309-310
    • Wells, A.U.1
  • 9
    • 84901817527 scopus 로고    scopus 로고
    • Staging of idiopathic pulmonary fibrosis: Past, present and future
    • Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23: 220-224.
    • (2014) Eur Respir Rev , vol.23 , pp. 220-224
    • Kolb, M.1    Collard, H.R.2
  • 10
    • 84861162888 scopus 로고    scopus 로고
    • A multidimensional index and staging system for idiopathic pulmonary fibrosis
    • Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
    • (2012) Ann Intern Med , vol.156 , pp. 684-691
    • Ley, B.1    Ryerson, C.J.2    Vittinghoff, E.3
  • 11
    • 84958040637 scopus 로고    scopus 로고
    • Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline
    • Salisbury ML, Xia M, Zhou Y, et al. Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline. Chest 2016; 149: 491-498.
    • (2016) Chest , vol.149 , pp. 491-498
    • Salisbury, M.L.1    Xia, M.2    Zhou, Y.3
  • 12
    • 84901759236 scopus 로고    scopus 로고
    • A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    • King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
    • (2014) N Engl J Med , vol.370 , pp. 2083-2092
    • King, T.E.1    Bradford, W.Z.2    Castro-Bernardini, S.3
  • 13
    • 79956341531 scopus 로고    scopus 로고
    • Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
    • Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
    • (2011) Lancet , vol.377 , pp. 1760-1769
    • Noble, P.W.1    Albera, C.2    Bradford, W.Z.3
  • 14
    • 84937574973 scopus 로고    scopus 로고
    • Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis
    • Lederer DJ, Bradford WZ, Fagan EA, et al. Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis. Chest 2015; 148: 196-201.
    • (2015) Chest , vol.148 , pp. 196-201
    • Lederer, D.J.1    Bradford, W.Z.2    Fagan, E.A.3
  • 16
    • 80051819865 scopus 로고    scopus 로고
    • Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
    • du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
    • (2011) Am J Respir Crit Care Med , vol.184 , pp. 459-466
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 17
    • 79955520497 scopus 로고    scopus 로고
    • Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
    • du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 1231-1237
    • Du Bois, R.M.1    Weycker, D.2    Albera, C.3
  • 18
    • 76549135612 scopus 로고    scopus 로고
    • The 6 minute walk in idiopathic pulmonary fibrosis: Longitudinal changes and minimum important difference
    • Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65: 173-177.
    • (2010) Thorax , vol.65 , pp. 173-177
    • Swigris, J.J.1    Wamboldt, F.S.2    Behr, J.3
  • 19
    • 84930960053 scopus 로고    scopus 로고
    • Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis
    • Nathan SD, du Bois RM, Albera C, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med 2015; 109: 914-922.
    • (2015) Respir Med , vol.109 , pp. 914-922
    • Nathan, S.D.1    Du Bois, R.M.2    Albera, C.3
  • 20
    • 84899830690 scopus 로고    scopus 로고
    • 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
    • du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 1421-1429.
    • (2014) Eur Respir J , vol.43 , pp. 1421-1429
    • Du Bois, R.M.1    Albera, C.2    Bradford, W.Z.3
  • 21
    • 84865207687 scopus 로고    scopus 로고
    • The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis
    • Swigris JJ, Han M, Vij R, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012; 106: 1447-1455.
    • (2012) Respir Med , vol.106 , pp. 1447-1455
    • Swigris, J.J.1    Han, M.2    Vij, R.3
  • 22
    • 85100415918 scopus 로고    scopus 로고
    • Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Date last accessed: November 17
    • Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org Date last accessed: November 17, 2015.
    • (2015) Cochrane Handbook for Systematic Reviews of Interventions
    • Higgins, J.P.T.1    Green, S.2
  • 23
    • 84906046346 scopus 로고    scopus 로고
    • IPF clinical trial design and endpoints
    • Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med 2014; 20: 463-471.
    • (2014) Curr Opin Pulm Med , vol.20 , pp. 463-471
    • Nathan, S.D.1    Meyer, K.C.2
  • 24
    • 77951170794 scopus 로고    scopus 로고
    • Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
    • Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
    • (2010) Eur Respir J , vol.35 , pp. 830-836
    • Zappala, C.J.1    Latsi, P.I.2    Nicholson, A.G.3
  • 25
    • 84975801947 scopus 로고    scopus 로고
    • Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS
    • Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-185.
    • (2016) Am J Respir Crit Care Med , vol.193 , pp. 178-185
    • Costabel, U.1    Inoue, Y.2    Richeldi, L.3
  • 26
    • 84954305088 scopus 로고    scopus 로고
    • Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from the three multinational phase 3 trials
    • Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from the three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
    • (2016) Eur Respir J , vol.47 , pp. 243-253
    • Noble, P.W.1    Albera, C.2    Bradford, W.Z.3
  • 27
    • 84938125365 scopus 로고    scopus 로고
    • An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline
    • Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
    • (2015) Am J Respir Crit Care Med , vol.192 , pp. e3-e19
    • Raghu, G.1    Rochwerg, B.2    Zhang, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.